AdvisorShares Investments LLC Reduces Stake in Thermo Fisher Scientific Inc. $TMO

AdvisorShares Investments LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 11,351 shares of the medical research company’s stock after selling 1,104 shares during the quarter. Thermo Fisher Scientific accounts for about 1.0% of AdvisorShares Investments LLC’s investment portfolio, making the stock its 29th biggest holding. AdvisorShares Investments LLC’s holdings in Thermo Fisher Scientific were worth $5,579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the company. High Note Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $28,000. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth approximately $28,000. Beacon Financial Strategies CORP bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Finally, Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Weiss Ratings cut shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price on the stock. Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research report on Thursday, May 14th. Morgan Stanley restated an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Finally, Barclays lowered their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $605.09.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 0.2%

NYSE TMO opened at $522.38 on Friday. The stock’s 50 day moving average is $473.17 and its 200 day moving average is $518.15. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99. The stock has a market cap of $194.13 billion, a PE ratio of 28.72, a P/E/G ratio of 2.32 and a beta of 0.87. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same quarter last year, the business posted $5.15 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.